155 related articles for article (PubMed ID: 18022432)
21. Prognostic value of MYCN and ID2 overexpression in neuroblastoma.
Alaminos M; Gerald WL; Cheung NK
Pediatr Blood Cancer; 2005 Dec; 45(7):909-15. PubMed ID: 16047351
[TBL] [Abstract][Full Text] [Related]
22. Association of high-level MRP1 expression with poor clinical outcome in a large prospective study of primary neuroblastoma.
Haber M; Smith J; Bordow SB; Flemming C; Cohn SL; London WB; Marshall GM; Norris MD
J Clin Oncol; 2006 Apr; 24(10):1546-53. PubMed ID: 16575006
[TBL] [Abstract][Full Text] [Related]
23. c.1810C>T polymorphism of NTRK1 gene is associated with reduced survival in neuroblastoma patients.
Lipska BS; Drozynska E; Scaruffi P; Tonini GP; Izycka-Swieszewska E; Zietkiewicz S; Balcerska A; Perek D; Chybicka A; Biernat W; Limon J
BMC Cancer; 2009 Dec; 9():436. PubMed ID: 20003389
[TBL] [Abstract][Full Text] [Related]
24. Hyperdiploidy plus nonamplified MYCN confers a favorable prognosis in children 12 to 18 months old with disseminated neuroblastoma: a Pediatric Oncology Group study.
George RE; London WB; Cohn SL; Maris JM; Kretschmar C; Diller L; Brodeur GM; Castleberry RP; Look AT
J Clin Oncol; 2005 Sep; 23(27):6466-73. PubMed ID: 16116152
[TBL] [Abstract][Full Text] [Related]
25. Prognostic significance of EPHB6, EFNB2, and EFNB3 expressions in neuroblastoma.
Tang XX; Zhao H; Robinson ME; Cnaan A; London W; Cohn SL; Cheung NK; Brodeur GM; Evans AE; Ikegaki N
Med Pediatr Oncol; 2000 Dec; 35(6):656-8. PubMed ID: 11107140
[TBL] [Abstract][Full Text] [Related]
26. Correlation of MYCN amplification with MCM7 protein expression in neuroblastomas: a chromogenic in situ hybridization study in paraffin sections.
Tsai HY; Hsi BL; Hung IJ; Yang CP; Lin JN; Chen JC; Tsai SF; Huang SF
Hum Pathol; 2004 Nov; 35(11):1397-403. PubMed ID: 15668898
[TBL] [Abstract][Full Text] [Related]
27. Cap43/NDRG1/Drg-1 is a molecular target for angiogenesis and a prognostic indicator in cervical adenocarcinoma.
Nishio S; Ushijima K; Tsuda N; Takemoto S; Kawano K; Yamaguchi T; Nishida N; Kakuma T; Tsuda H; Kasamatsu T; Sasajima Y; Kage M; Kuwano M; Kamura T
Cancer Lett; 2008 Jun; 264(1):36-43. PubMed ID: 18281151
[TBL] [Abstract][Full Text] [Related]
28. [Study on MYCN gene amplification and CD44 expression in neuroblastoma].
Hu HL; He LJ
Zhonghua Bing Li Xue Za Zhi; 2004 Aug; 33(4):332-6. PubMed ID: 15363318
[TBL] [Abstract][Full Text] [Related]
29. N-myc downstream-regulated gene 1/Cap43 expression promotes cell differentiation of human osteosarcoma cells.
Matsugaki T; Zenmyo M; Hiraoka K; Fukushima N; Shoda T; Komiya S; Ono M; Kuwano M; Nagata K
Oncol Rep; 2010 Sep; 24(3):721-5. PubMed ID: 20664979
[TBL] [Abstract][Full Text] [Related]
30. N-myc downstream regulated gene1/Cap43 overexpression suppresses tumor growth by hepatic cancer cells through cell cycle arrest at the G0/G1 phase.
Akiba J; Murakami Y; Noda M; Watari K; Ogasawara S; Yoshida T; Kawahara A; Sanada S; Yasumoto M; Yamaguchi R; Kage M; Kuwano M; Ono M; Yano H
Cancer Lett; 2011 Nov; 310(1):25-34. PubMed ID: 21775055
[TBL] [Abstract][Full Text] [Related]
31. Different effects of TrkA expression in neuroblastoma cell lines with or without MYCN amplification.
Eggert A; Ho R; Ikegaki N; Liu XG; Brodeur GM
Med Pediatr Oncol; 2000 Dec; 35(6):623-7. PubMed ID: 11107132
[TBL] [Abstract][Full Text] [Related]
32. Overexpression of Cap43 gene in supraglottic laryngeal squamous cell carcinoma.
Li X; Sakamoto K; Takahashi Y; Nakashima T
J Laryngol Otol Suppl; 2009; (31):11-7. PubMed ID: 19460198
[TBL] [Abstract][Full Text] [Related]
33. Prognostic significance of MYCN oncogene expression in childhood neuroblastoma.
Bordow SB; Norris MD; Haber PS; Marshall GM; Haber M
J Clin Oncol; 1998 Oct; 16(10):3286-94. PubMed ID: 9779703
[TBL] [Abstract][Full Text] [Related]
34. Prediction of clinical outcome and biological characterization of neuroblastoma by expression profiling.
Schramm A; Schulte JH; Klein-Hitpass L; Havers W; Sieverts H; Berwanger B; Christiansen H; Warnat P; Brors B; Eils J; Eils R; Eggert A
Oncogene; 2005 Nov; 24(53):7902-12. PubMed ID: 16103881
[TBL] [Abstract][Full Text] [Related]
35. Favorable prognosis for patients 12 to 18 months of age with stage 4 nonamplified MYCN neuroblastoma: a Children's Cancer Group Study.
Schmidt ML; Lal A; Seeger RC; Maris JM; Shimada H; O'Leary M; Gerbing RB; Matthay KK
J Clin Oncol; 2005 Sep; 23(27):6474-80. PubMed ID: 16116154
[TBL] [Abstract][Full Text] [Related]
36. Increased expression of a Myc target gene Mina53 in human colon cancer.
Teye K; Tsuneoka M; Arima N; Koda Y; Nakamura Y; Ueta Y; Shirouzu K; Kimura H
Am J Pathol; 2004 Jan; 164(1):205-16. PubMed ID: 14695334
[TBL] [Abstract][Full Text] [Related]
37. The MYCN oncogene and differentiation in neuroblastoma.
Westermark UK; Wilhelm M; Frenzel A; Henriksson MA
Semin Cancer Biol; 2011 Oct; 21(4):256-66. PubMed ID: 21849159
[TBL] [Abstract][Full Text] [Related]
38. Enlarged and prominent nucleoli may be indicative of MYCN amplification: a study of neuroblastoma (Schwannian stroma-poor), undifferentiated/poorly differentiated subtype with high mitosis-karyorrhexis index.
Kobayashi C; Monforte-Munoz HL; Gerbing RB; Stram DO; Matthay KK; Lukens JN; Seeger RC; Shimada H
Cancer; 2005 Jan; 103(1):174-80. PubMed ID: 15549714
[TBL] [Abstract][Full Text] [Related]
39. The presence of Y674/Y675 phosphorylated NTRK1 via TP53 repression of PTPN6 expression as a potential prognostic marker in neuroblastoma.
Youssef G; Gillett C; Rampling D; Chagtai T; Virasami A; Barton J; Edwards D; Sebire N; Anderson J; Montano X
Hum Pathol; 2019 Apr; 86():182-192. PubMed ID: 30594749
[TBL] [Abstract][Full Text] [Related]
40. MYCN amplification confers enhanced folate dependence and methotrexate sensitivity in neuroblastoma.
Lau DT; Flemming CL; Gherardi S; Perini G; Oberthuer A; Fischer M; Juraeva D; Brors B; Xue C; Norris MD; Marshall GM; Haber M; Fletcher JI; Ashton LJ
Oncotarget; 2015 Jun; 6(17):15510-23. PubMed ID: 25860940
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
